Estimating the Prevalence and Characteristics of Patients Potentially Eligible for Lipoprotein(a)-Lowering Therapies in a Real-World Setting
Arrigo F G Cicero, Federica Fogacci, Marina Giovannini, Elisa Grandi, Sergio D’Addato, Claudio Borghi, Patrick W Serruys, Tsung-Ying Tsai, Pruthvi C Revaiah · 2023
Read Estimating the Prevalence and Characteristics of Patients Potentially Eligible for Lipoprotein(a)-Lowering Therapies in a Real-World Setting by Arrigo F G Cicero, Federica Fogacci, Marina Giovannini, Elisa Grandi, Sergio D’Addato, Claudio Borghi, Patrick W Serruys, Tsung-Ying Tsai, Pruthvi C Revaiah (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10741849.txt.
Description
Arrigo Cicero and co-authors count how many clinic patients might qualify for new drugs that lower lipoprotein(a), a fatty particle tied to heart disease, in a 2023 study. High levels of the particle raise the risk of clogged arteries, and targeted drugs are on the way. The team pool records from about 6,000 Italian outpatients with lipid problems.
Among patients who already had artery disease, about 45 percent had particle levels above the cut-off for the new drugs. Age, standard cholesterol, and the particle itself each predicted who had disease. A further slice of patients sat just below the cut-off, near 5 to 7 percent in primary and secondary prevention groups. The pool of candidates is large, the authors say, even under a strict reading of the rules.
Catalog record
| CREATOR | Arrigo F G Cicero, Federica Fogacci, Marina Giovannini, Elisa Grandi, Sergio D’Addato, Claudio Borghi, Patrick W Serruys, Tsung-Ying Tsai, Pruthvi C Revaiah |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 32 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |